14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease

Gastroesophageal Reflux Disease (GERD) in Women

Gastroesophageal reflux disease (GERD) is characterized by retrograde flow of gastroduodenal contents into the esophagus, producing bothersome symptoms or mucosal injury.

Pathophysiologic Mechanisms & Female Hormones

Reflux is primarily driven by transient lower esophageal sphincter relaxations (TLESRs)—abrupt vasovagal relaxations of the lower esophageal sphincter (LES) unassociated with swallowing. Contributing factors include low resting LES tone (<10 mmHg), sliding hiatal hernia, impaired esophageal clearance, and delayed gastric emptying. In women, sex hormones exert direct effects: progesterone relaxes gastrointestinal smooth muscle, lowering LES basal pressure during the luteal phase of menses and throughout gestation, where elevated progesterone combines with gravid uterine compression to cause pyrosis in up to 80% of pregnant women.

Clinical Presentation: Esophageal vs. Extraesophageal Symptoms

• Classic Esophageal Symptoms: Pyrosis (substernal burning pain occurring 30 to 60 minutes postprandially and worsened by recumbency or bending forward) and acid regurgitation (sour fluid rising into the hypopharynx).
• Extraesophageal Symptoms: Chronic dry cough, morning hoarseness, asthma exacerbation, globus sensation, dental enamel erosion, and non-cardiac chest pain (which mimics myocardial ischemia and mandates ruling out acute coronary syndrome first).

---

Diagnostic Approach & Endoscopic Alarm Indicators

In women presenting with typical pyrosis and regurgitation and no alarm features, clinical guidelines endorse an empiric 4- to 8-week trial of once-daily proton pump inhibitor (PPI) therapy as both diagnostic and therapeutic.

Indications for Upper Endoscopy (EGD) & Alarm Signs

Diagnostic upper endoscopy (esophagogastroduodenoscopy [EGD]) is mandatory when patients exhibit any of the following alarm features, fail twice-daily PPI therapy, or require screening for Barrett esophagus:

Barrett Esophagus Surveillance

Chronic reflux can induce Barrett esophagus, the metaplastic replacement of stratified squamous epithelium with specialized intestinal columnar epithelium containing goblet cells. Barrett esophagus is a premalignant precursor to esophageal adenocarcinoma. Patients with confirmed Barrett esophagus without dysplasia require surveillance EGD every 3 to 5 years.

---

Stepwise Management of GERD & Long-Term PPI Safety

1. Lifestyle & Behavioral Interventions

• Weight Loss: Reduces intragastric pressure, providing significant reflux relief in women with overweight or obesity.
• Head of Bed Elevation: Elevate the head of the bed by 6 to 8 inches (15–20 cm) using bedframe risers or a firm foam wedge pillow. Gravity prevents nocturnal esophageal acid exposure.
• Postprandial Positioning: Avoid lying down or assuming recumbency for at least 2 to 3 hours following meals.
• Dietary Trigger Avoidance: Eliminate triggers that relax the LES or irritate mucosa: high-fat meals, caffeine, chocolate, peppermint, citrus fruits, tomato-based foods, alcohol, and carbonated beverages.

2. Pharmacotherapy: Antacids, H2RAs, and PPIs

• Antacids & Alginates: (Calcium carbonate, magnesium hydroxide). Provide rapid neutralization of gastric acid lasting 30 to 60 minutes. Safe for episodic mild heartburn and first-line in pregnancy.
• H2-Receptor Antagonists (H2RAs): (Famotidine 20–40 mg once or twice daily). Competitively inhibit H2 receptors on gastric parietal cells. Effective for mild-to-moderate symptoms or nocturnal breakthrough. Safe during pregnancy and lactation; chronic daily use induces tachyphylaxis within 2 to 6 weeks.
• Proton Pump Inhibitors (PPIs): (Omeprazole 20–40 mg, Pantoprazole 40 mg daily). Irreversibly inhibit H+/K+ ATPase pumps in parietal cells. Patient Counseling: PPIs must be taken strictly 30 to 60 minutes before the first meal of the day, when the maximal number of proton pumps are recruited.

3. Long-Term PPI Safety Risks & Deprescribing

Chronic, uninterrupted PPI therapy carries recognized physiologic complications resulting from hypochlorhydria:

• Micronutrient Malabsorption: Impaired acid-mediated ionization of vitamin B12 and non-heme iron, and reduced solubility of calcium carbonate (calcium citrate remains absorbed independent of acid).
• Bone Fractures & Osteopenia: Increased risk of hip, wrist, and spine fractures in postmenopausal women.
• Hypomagnesemia: Impaired intestinal magnesium transport; can produce tetany and arrhythmias; monitor serum magnesium periodically.
• Enteric Infections: Doubled risk of Clostridioides difficile colitis and bacterial gastroenteritis.
• Acute Interstitial Nephritis (AIN): Idiosyncratic immune reaction causing renal impairment.

---

Irritable Bowel Syndrome (IBS): Rome IV Diagnostic Framework

Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits without identifiable structural pathology. It demonstrates a 2- to 3-fold higher prevalence in females, with symptoms fluctuating across the menstrual cycle (worsening pain and looser stools during the late luteal and early menses phases due to progesterone drop and prostaglandin surge).

Rome IV Diagnostic Criteria

Diagnosis requires recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following:

1. Related to defecation (either improved or worsened by defecation).
2. Associated with a change in stool frequency (more or fewer bowel movements).
3. Associated with a change in stool form / appearance (stools becoming looser or harder, graded on the Bristol Stool Form Scale).

Criteria must be fulfilled for the preceding 3 months, with initial symptom onset occurring at least 6 months prior to clinical evaluation.

Subtype Classification (Bristol Stool Form Scale)

Subtyping guides targeted pharmacotherapy, assessed on days when bowel movements are abnormal:

• IBS with Constipation (IBS-C): >25% hard or lumpy stools (Bristol Types 1–2) and <25% loose or watery stools (Bristol Types 6–7).
• IBS with Diarrhea (IBS-D): >25% loose or watery stools (Bristol Types 6–7) and <25% hard or lumpy stools (Bristol Types 1–2).
• IBS with Mixed Bowel Habits (IBS-M): >25% hard or lumpy stools AND >25% loose or watery stools.
• IBS Unclassified (IBS-U): Meets pain criteria whose stool consistency abnormalities do not fit into other categories.

Diagnostic Workup & Exclusion of Organic Disease

In young female patients meeting Rome IV criteria without alarm features, invasive testing is unnecessary. The ACG recommends a limited diagnostic evaluation:

• Complete Blood Count (CBC) to screen for anemia
• C-reactive protein (CRP) or fecal calprotectin (FCP) to rule out Inflammatory Bowel Disease
• Serologic celiac disease screening with serum IgA tissue transglutaminase (tTG-IgA)
• Routine colonoscopy is NOT indicated in patients under age 45 unless alarm features are present (rectal bleeding, nocturnal diarrhea awakening the patient, unintended weight loss, fever, or family history of colorectal cancer or IBD).

---

Evidence-Based Management of IBS

Non-Pharmacologic Therapies

• Soluble Fiber: Psyllium (ispaghula husk) 10 to 25 grams daily improves symptoms and stool transit. Insoluble fiber (coarse wheat bran) often worsens bloating and gas.
• Low-FODMAP Diet: Restricts Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols. Implemented under registered dietitian guidance in three phases: Elimination (2–6 weeks), Reintroduction, and Personalization.
• Psychological Therapies: Gut-directed cognitive behavioral therapy (CBT) and hypnotherapy modulate the bidirectional brain-gut axis.

Pharmacotherapy for IBS Subtypes

• Antispasmodics: (Dicyclomine 10–20 mg, Hyoscyamine 0.125–0.25 mg taken 30–60 minutes before meals). Anticholinergics that blunt postprandial cramping; adverse effects include dry mouth and blurred vision.
• Targeted Agents for IBS-C:
  • Osmotic Laxatives: Polyethylene glycol (PEG 3350) softens stool but does not significantly reduce abdominal pain.
  • Intestinal Secretagogues: Lubiprostone (8 mcg BID in adult women), a type-2 chloride channel (ClC-2) activator; Linaclotide (72–290 mcg daily) and Plecanatide, guanylate cyclase-C (GC-C) agonists that increase luminal fluid secretion, accelerate transit, and dampen nociceptive pain signaling.
• Targeted Agents for IBS-D:
  • Peripheral Opioid Agonists: Loperamide (2–4 mg titrated) slows transit but does not relieve visceral pain.
  • Non-Absorbable Antibiotic: Rifaximin (550 mg TID for 14 days). Modulates the colonic microbiome, suppresses gas production, and relieves bloating and diarrhea.
  • 5-HT3 Receptor Antagonists: Alosetron (0.5–1.0 mg daily or BID). Serotonin antagonist approved strictly for women with severe chronic IBS-D refractory to conventional therapies. Due to risks of ischemic colitis and serious constipation complications, alosetron is distributed under an FDA-mandated REMS program.
  • Neuromodulators: Low-dose Tricyclic Antidepressants (TCAs) (Amitriptyline 10–25 mg at bedtime) blunt central pain processing and prolong transit time in IBS-D.

---

Gallbladder Disease: Cholelithiasis, Biliary Colic & Acute Cholecystitis

Gallstone disease demonstrates a 2- to 3-fold higher incidence in women than men during reproductive years.

Hormonal Pathogenesis: Estrogen, Progesterone & "The 4 Fs"

The clinical mnemonic "Female, Fat, Fertile, Forty" encapsulates core pathophysiologic mechanisms driven by sex hormones:

1. Estrogen Drives Cholesterol Supersaturation: Estrogen upregulates hepatic HMG-CoA reductase activity, enhancing cholesterol synthesis and hypersecreting cholesterol into bile. Bile becomes supersaturated, precipitating cholesterol monohydrate crystal nucleation and stone formation.
2. Progesterone Drives Gallbladder Hypomotility & Stasis: Progesterone impairs gallbladder smooth muscle contraction by diminishing cholecystokinin (CCK) receptor sensitivity. Gallbladder hypomotility leads to bile stasis, allowing cholesterol crystals to aggregate into macro-calculi. Pregnancy, high-dose oral contraceptives, and multiparity accelerate lithogenesis.
3. Metabolic Factors: Obesity and rapid weight loss (e.g., post-bariatric surgery) dramatically elevate biliary cholesterol saturation.

Clinical Spectrum: Biliary Colic vs. Acute Cholecystitis

The Murphy Sign

A hallmark bedside clinical physical finding in acute cholecystitis. The examiner deeply palpates the patient's right subcostal margin while the patient inspires deeply. As the inflamed gallbladder contacts the examiner's fingers, the patient experiences sudden sharp pain and exhibits an abrupt arrest of inspiratory effort (inspiratory arrest = positive Murphy sign).

Diagnostic Imaging Modalities

• Transabdominal Ultrasonography: The initial imaging modality of choice (sensitivity and specificity >95% for cholelithiasis). Sonographic findings diagnostic of acute cholecystitis include:
  1. Gallstones or biliary sludge with posterior acoustic shadowing.
  2. Gallbladder wall thickening (>3 mm).
  3. Pericholecystic fluid halo (extraluminal fluid accumulation).
  4. Sonographic Murphy Sign: Maximal focal tenderness elicited directly over the sonographically visualized gallbladder using the ultrasound transducer.
• Cholescintigraphy (HIDA Scan): Technetium-99m labeled hepatobiliary iminodiacetic acid is injected IV and excreted into bile. If the gallbladder is not visualized within 1 to 4 hours while the radiotracer freely enters the common bile duct and duodenum, cystic duct obstruction is confirmed, establishing definitive diagnosis of acute cholecystitis (indicated when ultrasound is equivocal).